NCT06609343Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis (BRISK)
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
Fatigue is the most common symptom reported by end-stage kidney disease patients on maintenance hemodialysis. Unfortunately, there currently is no medical management for this overwhelming feeling of tiredness. As a result, patients continue to suffer with poor quality of life and impaired daily activities. The purpose of this pilot trial is to find out if bupropion (a medicine commonly prescribed for stopping smoking, seasonal mood disorder, and depression) may help lessen fatigue in hemodialysis patients. In this study, hemodialysis participants will receive bupropion tablet orally three times a week during routine dialysis procedure for consecutive 8 weeks. Study participants will complete a battery of questionnaires to self-report fatigue, cognition, and quality of life. The study team will collect biological specimens. All these procedures will be performed at the dialysis clinic during routine dialysis procedure.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- First submitted
- 20 Sept 2024
- Start date
- Feb 2027
- Primary completion date
- Feb 2028
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Diseases
- Chronic kidney disease
- NCT number
- NCT06609343
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 16
- From Feb 2027 to the primary completion date, Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently on bupropion or hypersensitivity/ intolerance to bupropion by history and monoamine oxidase inhibitors.
- Scheduled for kidney transplantation in next 6 months
Other illness
- Diagnosis or history of eating disorders (bulimia or anorexia nervosa) and seizure.
- History of post-acute COVID-19 syndrome
- Diagnosis of depression and/or on antidepressants and bipolar affective disorder
- Diagnosis of cognitive impairment including dementia
- Current or history of substance abuse or dependency.
Other
- Pregnant, lactating, childbearing women
- Patient Health Questionnaire (PHQ)-9 score of ≥10
- Current participation in another interventional trial
- Life expectancy \<6 months as judged by the attending nephrologist/primary care physician.
Who the study is looking for
- Male and female ESKD patients between aged 25-74 yrs on maintenance in-center hemodialysis procedure 3 times/week for ≥3 months with an arteriovenous fistula or graft.
- Blood hemoglobin of ≥10.0 g/dL based on most recent routine laboratory profile.
- Dialysis adequacy measured with Kt/V of ≥1.2
- Ability to understand and the willingness to sign a written informed consent document
Age in the registry: 25 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Dialysis Medical Center (DMC) Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.